New RNA drug aims to reverse liver damage in NASH patients

NCT ID NCT06322628

Ongoing Disease control Sponsor: Visirna Therapeutics HK Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to cirrhosis. VSA006 is an RNA-based drug designed to lower a liver protein linked to disease progression. The study compares VSA006 injections every 12 weeks against a placebo, measuring improvements in liver scarring and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VSA006 (a type of RNA drug called siRNA that targets a liver protein linked to NASH)
What this could lead to: If successful, this could lead to a new treatment that slows or reverses liver damage in people with NASH, reducing the risk of cirrhosis.
What could go wrong: This is an early phase 2 trial with only 48 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH

Contacts and locations

Locations

Beijing Tsinghua Changgeng Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.